ArticleInternational journal of molecular sciences2024
Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less
Jennie Petterson, Dyar Mustafa, Sashidar Bandaru, Ella Äng Eklund, Andreas Hallqvist, Volkan I Sayin, Andréanne Gagné, Henrik Fagman, Levent M Akyürek
Open access · goldAbstract read
In one paragraphArticle in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors at 2 institutions in 2 countries.
Jennie PettersonDepartment of Clinical Pathology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden.
Dyar MustafaDepartment of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Sahlgrenska Academy, 405 30 Gothenburg, Sweden.
Sashidar BandaruDepartment of Clinical Pathology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden.
Ella Äng EklundSahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sahlgrenska Academy, 405 30 Gothenburg, Sweden.ORCID 0000-0002-7962-6836 Andreas HallqvistSahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sahlgrenska Academy, 405 30 Gothenburg, Sweden.ORCID 0000-0002-3705-194X Volkan I SayinSahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sahlgrenska Academy, 405 30 Gothenburg, Sweden.ORCID 0000-0002-5225-8260 Andréanne GagnéDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Henrik FagmanDepartment of Clinical Pathology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden.
Levent M AkyürekDepartment of Clinical Pathology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden.ORCID 0000-0002-1968-6458 Sahlgrenska University Hospital · SEBrigham and Women's Hospital · US
Funding
Adlerbertska Forskningsstiftelsen GU 2020/751ALF fund from the Sahlgrenska Academy Hospital in the Västra Götalandsre-gionen ALFGBG-495961Assar Gabrielsson's Foundation FB20-87Strategic Fund from the Institute of Biomedicine, University of Gothenburg, the Swedish Cancer Foundation 17 0171
6 · The paper itselfAbstract
Pulmonary adenocarcinoma (ADC) is a very diverse disease, both genetically and histologically, which displays extensive intratumor heterogeneity with numerous acquired mutations. ADC is the most common type of lung cancer and is believed to arise from adenocarcinoma in situ (AIS) which then progresses to minimally invasive adenocarcinoma (MIA). In patients of European ethnicity, we analyzed genetic mutations in AIS (
Indexed as
AdenocarcinomaAdenocarcinoma in SituAdenocarcinoma of LungLung NeoplasmsErbB ReceptorsHumansMutationProto-Oncogene Proteins p21(ras)EGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)biomarkerEGFRKRASlung adenocarcinomamutation
Identifiers
PMID38474205
PMCPMC10932068
OpenAlexW4392376708
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390